Surgery Partners (NASDAQ:SGRY) Price Target Cut to $21.00 by Analysts at UBS Group

Surgery Partners (NASDAQ:SGRY) had its price objective reduced by UBS Group from $29.00 to $21.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also weighed in on the company. Barclays lowered their price objective on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a report on Wednesday. Mizuho lowered their target price on Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. dropped their price objective on Surgery Partners from $27.00 to $20.00 and set a “neutral” rating on the stock in a report on Monday, November 24th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.45.

Surgery Partners Trading Up 0.2%

Shares of SGRY opened at $14.11 on Thursday. Surgery Partners has a 12-month low of $12.25 and a 12-month high of $24.64. The firm has a market capitalization of $1.83 billion, a P/E ratio of -22.76 and a beta of 1.95. The firm has a 50-day moving average price of $15.25 and a 200 day moving average price of $18.21. The company has a current ratio of 1.87, a quick ratio of 1.72 and a debt-to-equity ratio of 1.15.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The firm had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same quarter in the previous year, the firm earned $0.44 earnings per share. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. Sell-side analysts forecast that Surgery Partners will post 0.67 EPS for the current year.

Surgery Partners announced that its board has authorized a stock buyback plan on Thursday, February 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase up to 9.7% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Institutional Trading of Surgery Partners

Institutional investors and hedge funds have recently bought and sold shares of the business. Alpine Global Management LLC purchased a new position in Surgery Partners during the 4th quarter worth $175,000. Empowered Funds LLC raised its stake in shares of Surgery Partners by 1,340.9% during the 4th quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock worth $2,494,000 after buying an additional 150,216 shares in the last quarter. One68 Global Capital LLC acquired a new stake in Surgery Partners in the fourth quarter valued at $371,000. Man Group plc acquired a new stake in shares of Surgery Partners in the fourth quarter valued at about $5,080,000. Finally, Inspire Investing LLC boosted its stake in shares of Surgery Partners by 45.4% during the 4th quarter. Inspire Investing LLC now owns 30,073 shares of the company’s stock worth $465,000 after acquiring an additional 9,384 shares in the last quarter.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Company expansion and strategic deal — Surgery Partners completed the acquisition of Preferred Vascular Group (an ASC operator focused on dialysis-access procedures), expanding its ASC footprint and specialized services. ZIEGLER ADVISES PREFERRED VASCULAR GROUP ON ITS ACQUISITION BY SURGERY PARTNERS
• Positive Sentiment: Shareholder-friendly capital allocation — the board authorized a $200 million buyback (up to ~9.7% of shares), signaling management believes shares are undervalued and supporting EPS/ownership over time. Stock Buybacks
• Neutral Sentiment: Analysts still constructive but revising models — UBS, TD Cowen and Mizuho maintained buy/outperform ratings while cutting price targets (UBS to $21, TD Cowen to $20, Mizuho to $17), reflecting lowered near‑term expectations but continued confidence in recovery potential. Analyst Price Target Coverage TD Cowen PT Cut
• Neutral Sentiment: Earnings were mixed — Q4 showed revenue growth but margin pressures and an EPS miss, which explains both cautious analyst revisions and the short‑term stock weakness. Q4 2025 Earnings Call Highlights
• Negative Sentiment: Price targets and downside pressure — Barclays cut its target to $14 (roughly at the current level), adding downward pressure on sentiment. Barclays Lowers Price Target
• Negative Sentiment: Share price weakness and 52‑week low headlines — multiple outlets report SGRY hit a new 52‑week low after the disappointing earnings print, which can amplify selling and volatility. Sets New 52-Week Low MSN Coverage
• Negative Sentiment: Potential legal overhang — a law firm announced an investigation into possible claims against executives, which can elevate regulatory/legal risk and hurt sentiment until resolved. Johnson Fistel Investigation Notice

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.